Lineage Cell Therapeutics, Inc. Operating Lease, Payments
Lineage Cell Therapeutics, Inc. (LCTX) reported Operating Lease, Payments of $500.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-06
- Lineage Cell Therapeutics, Inc. operating lease, payments for the quarter ending 2026-06-30 was $187.00K, a 40.06% decline year-over-year.
- Lineage Cell Therapeutics, Inc. operating lease, payments for the quarter ending 2026-03-31 was $313.00K, a 2.62% increase year-over-year.
- Lineage Cell Therapeutics, Inc. operating lease, payments for the quarter ending 2025-12-31 was $309.00K, a 1.31% increase year-over-year.
- Lineage Cell Therapeutics, Inc. operating lease, payments for the quarter ending 2025-09-30 was $310.00K, a 1.31% increase year-over-year.
- Lineage Cell Therapeutics, Inc. operating lease, payments for fiscal 2025 was $1.24M, a 1.48% increase from fiscal 2024.
- Lineage Cell Therapeutics, Inc. operating lease, payments for fiscal 2024 was $1.22M, a 7.88% increase from fiscal 2023.
- Lineage Cell Therapeutics, Inc. operating lease, payments for fiscal 2023 was $1.13M, a 7.83% increase from fiscal 2022.
- Lineage Cell Therapeutics, Inc. operating lease, payments for fiscal 2022 was $1.05M, a 11.98% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $187.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $500.00K 10-Q · filed 2026-08-06 | $809.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.12M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $313.00K 10-Q · filed 2026-05-12 | $622.00K derived: sum of 2 quarters · filed 2026-05-12 | $932.00K derived: sum of 3 quarters · filed 2026-05-12 | $1.24M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $309.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $619.00K derived: sum of 2 quarters · filed 2026-03-05 | $931.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.24M 10-K · filed 2026-03-05 |
| 2025-09-30 | $310.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $622.00K derived: sum of 2 quarters · filed 2026-08-06 | $927.00K 10-Q · filed 2025-11-06 | $1.23M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $312.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $617.00K 10-Q · filed 2026-08-06 | $922.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.23M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $305.00K 10-Q · filed 2026-05-12 | $610.00K derived: sum of 2 quarters · filed 2026-05-12 | $916.00K derived: sum of 3 quarters · filed 2026-05-12 | $1.22M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $305.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $611.00K derived: sum of 2 quarters · filed 2026-03-05 | $916.00K derived: sum of 3 quarters · filed 2026-03-05 | $1.22M 10-K · filed 2026-03-05 |
| 2024-09-30 | $306.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $611.00K derived: sum of 2 quarters · filed 2025-11-06 | $913.00K 10-Q · filed 2025-11-06 | $1.21M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $305.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $607.00K 10-Q · filed 2025-08-12 | $903.00K derived: sum of 3 quarters · filed 2025-08-12 | $1.20M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $302.00K 10-Q · filed 2025-05-13 | $598.00K derived: sum of 2 quarters · filed 2025-05-13 | $893.00K derived: sum of 3 quarters · filed 2025-05-13 | $1.12M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $296.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $591.00K derived: sum of 2 quarters · filed 2025-03-10 | $814.00K derived: sum of 3 quarters · filed 2025-03-10 | $1.13M 10-K · filed 2025-03-10 |
| 2023-09-30 | $295.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $518.00K derived: sum of 2 quarters · filed 2024-11-14 | $833.00K 10-Q · filed 2024-11-14 | $1.15M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $223.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $538.00K 10-Q · filed 2024-08-08 | $858.00K derived: sum of 3 quarters · filed 2024-08-08 | $1.08M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $315.00K 10-Q · filed 2024-05-09 | $635.00K derived: sum of 2 quarters · filed 2024-05-09 | $854.00K derived: sum of 3 quarters · filed 2024-05-09 | $1.11M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $320.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $539.00K derived: sum of 2 quarters · filed 2024-03-07 | $792.00K derived: sum of 3 quarters · filed 2024-03-07 | $1.05M 10-K · filed 2024-03-07 |
| 2022-09-30 | $219.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $472.00K derived: sum of 2 quarters · filed 2023-11-09 | $727.00K 10-Q · filed 2023-11-09 | $975.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $253.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $508.00K 10-Q · filed 2023-08-10 | $756.00K derived: sum of 3 quarters · filed 2023-08-10 | $1.00M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $255.00K 10-Q · filed 2023-05-11 | $503.00K derived: sum of 2 quarters · filed 2023-05-11 | $752.00K derived: sum of 3 quarters · filed 2023-05-11 | $982.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $248.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $497.00K derived: sum of 2 quarters · filed 2023-03-09 | $727.00K derived: sum of 3 quarters · filed 2023-03-09 | $935.00K 10-K · filed 2023-03-09 |
| 2021-09-30 | $249.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $479.00K derived: sum of 2 quarters · filed 2022-11-10 | $687.00K 10-Q · filed 2022-11-10 | $886.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $230.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $438.00K 10-Q · filed 2022-08-11 | $637.00K derived: sum of 3 quarters · filed 2022-08-11 | $997.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $208.00K 10-Q · filed 2022-05-12 | $407.00K derived: sum of 2 quarters · filed 2022-05-12 | $767.00K derived: sum of 3 quarters · filed 2022-05-12 | $1.17M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $199.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $559.00K derived: sum of 2 quarters · filed 2022-03-10 | $958.00K derived: sum of 3 quarters · filed 2022-03-10 | $1.36M 10-K · filed 2022-03-10 |
| 2020-09-30 | $360.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $759.00K derived: sum of 2 quarters · filed 2021-11-10 | $1.16M 10-Q · filed 2021-11-10 | $1.50M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $399.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $797.00K 10-Q · filed 2021-08-12 | $1.14M derived: sum of 3 quarters · filed 2021-08-12 | $1.49M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $398.00K 10-Q · filed 2021-05-13 | $736.00K derived: sum of 2 quarters · filed 2021-05-13 | $1.09M derived: sum of 3 quarters · filed 2021-05-13 | $1.43M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $338.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $694.00K derived: sum of 2 quarters · filed 2021-03-11 | $1.03M derived: sum of 3 quarters · filed 2021-03-11 | $1.36M 10-K · filed 2021-03-11 |
| 2019-09-30 | $356.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $695.00K derived: sum of 2 quarters · filed 2020-11-04 | $1.03M 10-Q · filed 2020-11-04 | |
| 2019-06-30 | $339.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $670.00K 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $331.00K 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |